Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
复制标题
DOI：
10.3390/ijms18112469
复制
发表时间：
2017-11-20
影响因子：
5.6
通讯作者：
Steinbach JP
中科院分区：
文献类型：
--
作者：
Burger MC;Breuer S;Cieplik HC;Harter PN;Franz K;Bähr O;Steinbach JP
在胶质母细胞瘤患者中，贝伐单抗(Bev)的抗血管生成治疗已被证明可以提高无进展生存率(PFS)，但不能改善总生存率(OS)。尤其是在多灶性胶质母细胞瘤中具有不寻常的浸润性表型的患者，BEV疗法的使用仍然存在更大的争议。因此，我们准备了一个回顾性病例系列，包括16名接受BEV治疗的多灶性胶质母细胞瘤患者。我们将这些患者与16名接受BEV治疗的单一病变的胶质母细胞瘤患者进行了匹配的对照队列比较。这项研究的目的是评估具有多灶性疾病模式的胶质母细胞瘤患者的病程是否与仅有单一病变的患者不同。采用BEV单一疗法或BEV联合伊立替康或洛莫司汀(CCNU)治疗。两组的应答率和PFS相似。在多灶性胶质母细胞瘤患者组中，有一种不利于OS的趋势，这是由于多灶性胶质母细胞瘤的预后普遍较差而预期的。我们调查了Bev治疗是否影响了通过磁共振成像(MRI)上出现的新病变来衡量的侵袭性生长模式。在BEV治疗下，多灶性和孤立性胶质母细胞瘤的新病变发生率都有降低的趋势。根据这些结果，BEV疗法在多灶性胶质母细胞瘤中的复发率似乎不亚于单发胶质母细胞瘤。
In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still more controversial. Therefore, we prepared a retrospective case series with 16 patients suffering from a multifocal glioblastoma treated with BEV. We compared these patients to a matched control cohort of 16 patients suffering from glioblastoma with a single lesion treated with BEV. The objective of this study was to evaluate whether the course of disease differs in glioblastoma patients with a multifocal disease pattern compared to those with a single lesion only. Patients were treated with BEV monotherapy or BEV in combination with irinotecan or lomustine (CCNU). Response rates and PFS were similar in both groups. There was a trend for an unfavorable OS in the patient group with multifocal glioblastoma, which was expected due to the generally worse prognosis of multifocal glioblastoma. We investigated whether BEV therapy affects the invasive growth pattern as measured by the appearance of new lesions on magnetic resonance imaging (MRI). Under BEV therapy, there was a trend for a lower frequency of new lesions both in multifocal and solitary glioblastoma. Based on these results, BEV therapy at relapse appears to be justified to no lesser extent in multifocal glioblastoma than in solitary glioblastoma.
登录
查看更多内容
影响因子：
5.6
作者：
Burger MC;Mildenberger IC;Wagner M;Mittelbronn M;Steinbach JP;Bähr O
通讯作者：
Bähr O
影响因子：
15.9
作者：
Abou-El-Ardat K;Seifert M;Becker K;Eisenreich S;Lehmann M;Hackmann K;Rump A;Meijer G;Carvalho B;Temme A;Schackert G;Schröck E;Krex D;Klink B
通讯作者：
Klink B
影响因子：
4.1
作者：
Patil, Chirag G.;Yi, Anthony;Nuno, Miriam
通讯作者：
Nuno, Miriam
影响因子：
4.1
作者：
Silbergeld, DL;Chicoine, MR
通讯作者：
Chicoine, MR
影响因子：
15.9
作者：
Kickingereder, Philipp;Wiestler, Benedikt;Radbruch, Alexander
通讯作者：
Radbruch, Alexander